Clinical Trial

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-30; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT07010835
Lead Sponsor Excyte Biopharma Ltd
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 189 participants
Start Date 2025-08-25
Primary Completion 2027-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-05